Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether ...

Fintel reports that on July 11, 2025, Raymond James initiated coverage of Vir Biotechnology (NasdaqGS:VIR) with a Outperform ...

The question now is not whether AI can reshape biotechnology, but how far it can take us. Enjoyed this article?

As summer kicks into full gear and people are spending more time outside, there's one thing on many people's minds—ticks.

Scientists have identified dozens of human proteins that SARS-CoV-2, the virus that causes COVID-19, depends on to replicate ...

Virus Geeks is a data-driven Bio-Health Technology Company that develops health-centric initiatives to improve the quality of life through strategic partnerships across healthcare & biotechnology ...

There are almost no rules when it comes to publishing the blueprints needed to make or alter a virus with the tools of synthetic biology.

Resurrection biology — attempting to bring strings of molecules and more complex organisms back to life — is gaining traction in labs around the world.

Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for ...

Oncolytics Biotech Inc shares N.ONCY are trading up $0.09 at $1.01.

As summer kicks into full gear and people are spending more time outside, there's one thing on many people's minds - ticks.

Vir Biotechnology has demonstrated consistent progress in its clinical programs, particularly with the initiation of the ECLIPSE Phase III trials for hepatitis delta virus.